Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ: IOVA )

5.570 +0.230 (+4.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer. 
Via Benzinga
What's Wrong With Iovance Biotherapeutics Stock?
Via The Motley Fool
Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Via The Motley Fool
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
A handful of bullish factors are converging at the right time in the right way for all three of these companies. 
Via The Motley Fool
Iovance Biotherapeutics Shares Are Falling Today: What's Going On?
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). 
Via Benzinga
Prediction: This Stock Will Beat the Market in 2025
Via The Motley Fool
Peering Into Iovance Biotherapeutics's Recent Short Interest
Via Benzinga
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Via The Motley Fool
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
These windows of opportunity aren't likely to remain open for much longer. 
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Via The Motley Fool
A Peek at Iovance Biotherapeutics's Future Earnings
Via Benzinga
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough? 
Via The Motley Fool
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
3 Monster Stocks to Hold for the Next 10 Years
Just be ready to ride out some inevitable turbulence along the way. 
Via The Motley Fool
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
2 Innovative Stocks That Could Deliver Outsize Returns
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
Why Iovance Biotherapeutics Stock Triumphed on Thursday
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. 
Via The Motley Fool
Looking Into Iovance Biotherapeutics's Recent Short Interest
Via Benzinga
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon. 
Via The Motley Fool
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize. 
Via The Motley Fool
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Investors should brace for dilution. 
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback